All In Biotech

Free tool

FAERS Monitor: Zepatier

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 208261 or its brand name (Zepatier, Elbasvir, Grazoprevir). Reports on generic versions are filed under their own applications.

Reports

4,249

Serious

1,435

34% of reports

Hospitalization

575

Death reported

123

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • fatigue958
  • headache756
  • nausea558
  • insomnia313
  • diarrhoea256
  • drug dose omission253
  • vomiting182
  • adverse event150
  • pneumonia147
  • hepatitis c137
  • arthralgia133
  • pruritus123
  • dizziness122
  • pain122
  • joint swelling118

Reports by year received

View as table
YearReports
20152
2016656
20172,382
2018684
2019242
202079
202139
202230
202314
202469
202545
20267

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,049,910 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
hepatitis cSignal13756.848.17,375
adverse eventSignal1508.16.9924
drug dose omissionSignal2537.66.71,449
fatigueSignal9586.15.84,229
headacheSignal7566.05.63,219
insomniaSignal3135.85.21,260
joint swellingSignal1184.84.1358
nauseaSignal5583.53.21,028
pneumoniaSignal1472.21.9102
diarrhoea2562.01.7124
vomiting1821.91.781
pruritus1231.61.326
arthralgia1331.61.329
dizziness1221.21.04
pain1221.00.80

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.